These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease. Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA. Int Rev Neurobiol; 2011 Jan; 100():127-49. PubMed ID: 21971006 [Abstract] [Full Text] [Related]
29. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease. Nakamura Y, Arawaka S, Sato H, Sasaki A, Shigekiyo T, Takahata K, Tsunekawa H, Kato T. J Neurosci; 2021 Sep 01; 41(35):7479-7491. PubMed ID: 34290084 [Abstract] [Full Text] [Related]
30. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. Gerlach M, Desser H, Youdim MB, Riederer P. J Neural Transm Suppl; 1996 Sep 01; 48():7-21. PubMed ID: 8988458 [Abstract] [Full Text] [Related]
31. The pharmacology of selegiline. Magyar K. Int Rev Neurobiol; 2011 Sep 01; 100():65-84. PubMed ID: 21971003 [Abstract] [Full Text] [Related]
32. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. Goren T, Adar L, Sasson N, Weiss YM. J Clin Pharmacol; 2010 Dec 01; 50(12):1420-8. PubMed ID: 20445015 [Abstract] [Full Text] [Related]
36. Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G. J Neurol; 2017 Jun 01; 264(6):1254-1263. PubMed ID: 28550482 [Abstract] [Full Text] [Related]
37. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M. Br J Clin Pharmacol; 2018 Sep 01; 84(9):1917-1927. PubMed ID: 29847694 [Abstract] [Full Text] [Related]
38. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. Gal S, Fridkin M, Amit T, Zheng H, Youdim MB. J Neural Transm Suppl; 2006 Sep 01; (70):447-56. PubMed ID: 17017567 [Abstract] [Full Text] [Related]
39. Selective inhibitors of monoamine oxidase type B and the "cheese effect". Finberg JP, Gillman K. Int Rev Neurobiol; 2011 Sep 01; 100():169-90. PubMed ID: 21971008 [Abstract] [Full Text] [Related]
40. Rasagiline as a therapy for Parkinson's disease (PD). Hermanowicz N. Am J Geriatr Pharmacother; 2007 Jun 01; 5(2):174-5; author reply 175-6. PubMed ID: 17719520 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]